Abstract:Multiple preventive COVID-19 vaccines have been developed during the ongoing SARS coronavirus (CoV) 2 pandemic, utilizing a variety of technology platforms, which have different properties, advantages, and disadvantages. The acceleration in vaccine development required to combat the current pandemic is not at the expense of the necessary regulatory requirements, including robust and comprehensive data collection along with clinical product safety and efficacy evaluation. Due to the previous development of vaccine candidates against the related highly pathogenic coronaviruses SARS-CoV and MERS-CoV, the antigen that elicits immune protection is known: the surface spike protein of SARS-CoV-2 or specific domains encoded in that protein, e.g., the receptor binding domain. From a scientific point of view and in accordance with legal frameworks and regulatory practices, for the approval of a clinic trial, the Paul-Ehrlich-Institut requires preclinical testing of vaccine candidates, including general pharmacology and toxicology as well as immunogenicity. For COVID-19 vaccine candidates, based on existing platform technologies with a sufficiently broad data base, pharmacological–toxicological testing in the case of repeated administration, quantifying systemic distribution, and proof of vaccination protection in animal models can be carried out in parallel to phase 1 or 1/2 clinical trials. To reduce the theoretical risk of an increased respiratory illness through infection-enhancing antibodies or as a result of Th2 polarization and altered cytokine profiles of the immune response following vaccination, which are of specific concern for COVID-19 vaccines, appropriate investigative testing is imperative. In general, phase 1 (vaccine safety) and 2 (dose finding, vaccination schedule) clinical trials can be combined, and combined phase 2/3 trials are recommended to determine safety and efficacy. By applying these fundamental requirements not only for the approval and analysis of clinical trials but also for the regulatory evaluation during the assessment of marketing authorization applications, several efficacious and safe COVID-19 vaccines have been licensed in the EU by unprecedentedly fast and flexible procedures. Procedural and regulatory–scientific aspects of the COVID-19 licensing processes are described in this review.

Learning from the past: development of safe and effective COVID-19 vaccines

SARS-CoV-2: Mapping its features that made it as a unique virus

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Coronavirus vaccine development: from SARS and MERS to COVID-19

Status Report on COVID-19 Vaccines Development

The way of SARS-CoV-2 vaccine development: success and challenges

Advances in the Design and Development of SARS-CoV-2 Vaccines

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective

COVID-19 Vaccine Development: Milestones, Lessons and Prospects

COVID‐19 vaccine: recent advancements and future prospects

Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks

Challenges and Recent Advancements in COVID-19 Vaccines

Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges

SARS-CoV-2 Vaccine Development and Challenges

Recent Advances in Vaccine Development of Severe Acute Respiratory Syndrome Coronavirus 2

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development

SARS-CoV-2: vaccines in the pandemic era